Newsroom | 193060 results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

ADDISON, Texas--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its first quarter ended March 31, 2025, and the declaration of a cash dividend. “Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter. With a deep understanding of patient and client needs and market dynamics, we cont...

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2025, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended March 31, 2025 (compared to the three months ended March 31, 2024) Net sales of $347.8 million, an increase of $84.6 million, or 32% Net income of $20.9 million, an increase of $12.5 million Diluted earnin...

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the first quarter ended March 31, 2025. FINANCIAL HIGHLIGHTS Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles (“GAAP”) measure, was $19.5 million for the three months ended March 31, 2025 (“2025 First Quarter”), an increase of $2.8 million, or 1...

Venlo, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass sein Aufsichtsrat beabsichtigt, Stephen H. Rusckowski nach der Hauptversammlung am 26. Juni 2025 zum Nachfolger von Lawrence A. Rosen als Aufsichtsratsvorsitzenden zu wählen. Der Wechsel erfolgt, nachdem Herr Rosen beschlossen hat, sein Amt als Vorsitzender und Mitglied des Aufsichtsrates nach der Hauptversammlung niederzulegen. Herr Rosen gehört dem Aufsichtsrat seit 2013 an und...

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Meeting on June 26, 2025. The change comes after Mr. Rosen has decided to step down as Chairman of the Supervisory Board and as a Supervisory Board member upon completion of the Annual General Meeting. Mr. Rosen has served on...

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408       (23 ) %   (5 ) % Gross profit margin*   20.0   %   (40 ) bps   —   bps Net loss attributable to common stockholders $ (490 )     (118 ) %   87...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug (“veli”), the company’s lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of TED. Breakthrough Therapy D...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA...